arrow
D

Daniel A. Pollyea

university of colorado school of medicine
H指数:70
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia

一项CC-486和Venetoclax口服方案在急性髓系白血病中的I/1b期研究

2026-07-280
OA
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

新诊断急性髓系白血病患者的耐受性与结局:接受连续28天周期性Venetoclax治疗的研究

2026-02-130
PRE
The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells

STAT3-VDAC1轴调控线粒体功能并在急性髓系白血病细胞存活中发挥关键作用

2026-02-015
OA
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial

奥马曲拉和氮杂胞苷用于初治的伴有过多 blasts 的骨髓增生异常综合征患者的 I/II 期临床试验

2025-10-100
OAAI
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia

MICA/MICB的下调增强了NKG2DL CAR T细胞在复发或难治性急性髓系白血病或骨髓异常增生性肿瘤患者中的细胞持久性和临床活性。

Leukemia
IF13.4
2025-09-150
PRE
Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

已知预后模型无法预测Venetoclax和Azacitidine在复发/难治性急性髓系白血病中的结局:一项单中心回顾性分析

2025-08-140
PREAI
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia

去甲基化药物与Venetoclax联合方案是老年(≥70岁)新诊断低危急性髓系白血病患者接受强化化疗的安全有效替代方案。

2025-08-070
PREAI
PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

PTPN11基因突变与接受表观遗传药物(包括低甲基化剂和Venetoclax)治疗的急性髓系白血病患者生存期缩短相关。

BLOOD
IF23.1
2024-11-050
PRE
Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

奥马扎克汀和阿扎胞苷用于新诊断的伴有过多原始细胞的骨髓增生异常综合征患者

BLOOD
IF23.1
2024-11-050
PRE
Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents plus Venetoclax in Newly Diagnosed AML

免疫表型标志物CD7和CD56可改善一线低甲基化药物联合Venetoclax在初诊AML中的风险分层

BLOOD
IF23.1
2024-11-050
PRE
Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

深度学习基于骨髓涂片图像数据预测新诊断急性髓系白血病患者的维奈克拉和阿扎胞苷治疗反应

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

比较清髓性预处理与基于全身照射的方案与基于化疗的方案在成年接受脐带血干细胞移植治疗Ph阴性急性淋巴细胞白血病患者中的对比

BLOOD
IF23.1
2024-11-050
PRE
Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium
2024-05-231
OA